Device Trial Radar · NCT05245851
Clinical Deployment and Validation of Rho
Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,146
Actual
Start
Nov 21, 2022
Primary completion
Oct 1, 2023
Study completion Oct 1, 2023
Sponsor
- Lead sponsor
- 16 Bit Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Amgen; Sunnybrook Health Sciences Centre
- First posted
- Feb 18, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated device
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Osteoporosis is a widespread disease characterized by the loss of bone mineral density (BMD). 16 Bit has developed software, called RhoTM, that analyzes various x-rays, performed in patient age 50 and above for any clinical indication, to identify patients with low BMD. RhoTM is intended to function as a pre-screening device for low BMD. This study seeks to assess the clinical performance and impact of implementing RhoTM in real-world settings by analyzing its performance and impact on DXA referrals.
Conditions
- Low Bone Density
Interventions
Opportunistic screening for low BMDDevice
Software will analyze x-rays of the chest, thoracic spine, lumbar spine, pelvis, knee or hand/wrist acquired for any reason, and notify the radiologist at time of acquisition if low BMD is detected. The report to the radiologist includes the following statements: * This x-ray was opportunistically analyzed by RhoTM, an investigational device under ITA \[investigational testing authorization\] from Health Canada, to screen for low bone mineral density (low BMD). * This information should be used by a trained healthcare provider in conjunction with a patient's clinical fracture risk to determine if formal BMD screening with DXA is appropriate. The radiologist can choose to include this as an incidental finding in their report to the referring physician.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Positive predictive valueTime frame: 9 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Holland Orthopaedic & Arthritic Centre
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.